Author/Editor		Strojan, Primož; Budihna, Marjan; Šmid, Lojze; Svetic, Branka; Vrhovec, Ivan; Kos, Janko; Škrk, Janez
Title		Cysteine proteinase inhibitors stefin A a106nd stefin B in operable carcinoma of the head and neck
Translated title		Inhibitorji cisteinskih proteinaz stefin A in stefin B pri operabilnem karcinomu glave in vratu
Type		članek
Source		Radiol Oncol
Vol. and No.		Letnik 36, št. 2
Publication year		2002
Volume		str. 145-51
Language		eng
Abstract		Purpose. To evaluate the significance of cysteine proteinase inhibitors stefins (Stefs) A and B for a treatment decision and prognosis in operable squamous cell carcinoma of the head and neck (SCCHN). Patients and methods. Stefs A and B concentrations were determined immunobiochemically using ELISAs in cytosols prepared from the tumor and adjacent normal mucosa from 91 patients with operable SCCHN. The median follow-up period of patients alive at the close-out date was 5.8 years (range, 5-9.3 years). Results. Stef A concentrations were significantly higher in tumor compared to normal mucosa (FM.05). When a subgroup with clinically palpable nodes) at presentation was taken into consideration (n=57), a significant difference in Stef A (P=0.03) and Stef B (P=0.02) concentrations between those with negative and positive necks, as determined on histopathological examination, was observed. On the univariate survival analysis, higher Stefs' concentrations turned to be prognostically advantageous. Stef A proved its independent prognostic significance also on multivariate setting. Conclusions. With the capability to differentiate between the pN0- and pN+-stages of the disease in the patients originally presented as node-positive, Stefs A and B could be useful markers when deciding on the extent of neck surgery. In addition, both Stefs proved to be reliable prognosticators for survival in patients with operable SCCHN.
Summary		Namen. Ovrednotiti vlogo inhibitorjev cisteinskih proteinaz stefinov A in B v procesu odločanja o zdravljenju in njihov napovedni pomen pri operabilnem ploščatoceličnem karcinomu glave in vratu. Bolniki in metode. Koncentracije stefinov A in B so bile izmerjene imunobiokemično z uporabo ELISA testov v citosolih, pripravljenih iz tkiva tumorja in okolne zdrave sluznice 91 bolnikov z operabilnim ploščatoceličnim karcinomom glave in vratu. Ob zaključku opazovanega obdobja je znašal srednji čas spremljanja preživelih bolnikov 5,8 let (razpon 5-9,3 leta). Rezultati. Koncentracija stefina A je bila statistično pomembno višja v vzorcih tumorja kot v vzorcih zdrave sluznice (P=0.05). V skupini bolnikov s klinično tipnimi bezgavkami pred zdravljenjem (n=57) je bila ugotovljena signifikantna razlika v koncentracijah stefina A (P=0.03) in stefina B (P=0.02) med tistimi s histopatološko potrjeno prizadetostjo bezgavk in tistimi z neprizadetostjo vratnih bezgavk. V univariatni analizi preživetja so se kot prognostično ugodnejše izkazale visoke koncentracije stefinov. Stefin A je potrdil svoj neodvisen napovedni pomen tudi v multivariatni analizi. Zaključki. Kot dejavnika, zmožna razlikovati med patološkima stadijema bolezni pNo in pN+ pri bolnikih s klinično ugotovljeno prizadetostjo bezgavk, bi stefina A in B lahko vplivala na odločitev o obsegu operacije na vratu. Oba stefina sta se izkazala kot zanesljiva kazalca za napoved preživetja bolnikov z operabilnim ploščatoceličnim karcinomom glave in vratu.
Descriptors		HEAD AND NECK NEOPLASMS CARCINOMA, SQUAMOUS CELL CYSTEINE PROTEINASE INHIBITORS NEOPLASM STAGING DISEASE-FREE SURVIVAL